Cargando…

Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS

OBJECTIVE: Alemtuzumab exerts its clinical efficacy by its specific pattern of depletion and repopulation of different immune cells. Beyond long-term immunologic and clinical data, little is known about acute changes in immunologic and routine laboratory parameters and their clinical relevance durin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thomas, Katja, Eisele, Judith, Rodriguez-Leal, Francisco Alejandro, Hainke, Undine, Ziemssen, Tjalf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4853056/ https://www.ncbi.nlm.nih.gov/pubmed/27213173 http://dx.doi.org/10.1212/NXI.0000000000000228

Ejemplares similares

Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world
por: Ziemssen, Tjalf, et al.
Publicado: (2017)

Microscopic polyangiitis after alemtuzumab treatment in relapsing-remitting MS
por: Sauer, Eva-Maria, et al.
Publicado: (2018)

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients
por: Giovannoni, Gavin, et al.
Publicado: (2016)

Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies
por: Comi, Giancarlo, et al.
Publicado: (2019)

Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies
por: Van Wijmeersch, Bart, et al.
Publicado: (2019)

Nonwalking response to fampridine in patients with multiple sclerosis in a real-world setting
por: Rodriguez-Leal, Francisco Alejandro, et al.
Publicado: (2019)

Event-Driven Immunoprofiling Predicts Return of Disease Activity in Alemtuzumab-Treated Multiple Sclerosis
por: Akgün, Katja, et al.
Publicado: (2020)

Alemtuzumab: evidence for its potential in relapsing—remitting multiple sclerosis
por: Brown, JWL, et al.
Publicado: (2013)

Alemtuzumab: A new therapy for active relapsing–remitting multiple sclerosis
por: Hartung, Hans-Peter, et al.
Publicado: (2015)

Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years
por: Horáková, Dana, et al.
Publicado: (2020)

Alemtuzumab in a Large Real-Life Cohort: Interim Baseline Data of the TREAT-MS Study
por: Ziemssen, Tjalf, et al.
Publicado: (2021)

Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study
por: Coles, Alasdair J., et al.
Publicado: (2023)

Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing–remitting MS
por: Kuhle, Jens, et al.
Publicado: (2021)

Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies
por: Bertolotto, Antonio, et al.
Publicado: (2020)

Alemtuzumab improves contrast sensitivity in patients with relapsing–remitting multiple sclerosis
por: Graves, Jennifer, et al.
Publicado: (2013)

The use of alemtuzumab in patients with relapsing-remitting multiple sclerosis: the Gulf perspective
por: Alroughani, Raed, et al.
Publicado: (2020)

Fingolimod additionally acts as immunomodulator focused on the innate immune system beyond its prominent effects on lymphocyte recirculation
por: Thomas, Katja, et al.
Publicado: (2017)

Rescue therapy with alemtuzumab in B cell/antibody-mediated multiple sclerosis
por: Akgün, Katja, et al.
Publicado: (2018)

No Impact of Long-Term Fingolimod Treatment on Fecal Secretory Immunoglobulin A Levels in Patients With Multiple Sclerosis
por: Inojosa, Hernan, et al.
Publicado: (2020)

Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis
por: Guarnera, Cristina, et al.
Publicado: (2017)

Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis
por: Gilmore, Wendy, et al.
Publicado: (2020)

Immune Regulatory Cell Bias Following Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis
por: Kashani, Nicole, et al.
Publicado: (2021)

Sub-analysis of geographical variations in the 2-year observational COPTIMIZE trial of patients with relapsing–remitting multiple sclerosis converting to glatiramer acetate
por: Ziemssen, Tjalf, et al.
Publicado: (2015)

Acute Effects of Ocrelizumab Infusion in Multiple Sclerosis Patients
por: Akgün, Katja, et al.
Publicado: (2022)

Rationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS)
por: Ziemssen, Tjalf, et al.
Publicado: (2016)

Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis
por: Ziemssen, Tjalf, et al.
Publicado: (2008)

Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management
por: Cuker, Adam, et al.
Publicado: (2019)

Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing–remitting multiple sclerosis: an observational study
por: Zhukovsky, Christina, et al.
Publicado: (2021)

B-Cell Activity Predicts Response to Glatiramer Acetate and Interferon in Relapsing-Remitting Multiple Sclerosis
por: Tacke, Sabine, et al.
Publicado: (2021)

Alemtuzumab‐induced petechiae and epistaxis in a patient with relapsing–remitting multiple sclerosis: A case report
por: Mahmoudi, Farhad, et al.
Publicado: (2023)

Impact of alemtuzumab on health-related quality of life over 6 years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis
por: Arroyo, Rafael, et al.
Publicado: (2019)

Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS
por: Akgün, Katja, et al.
Publicado: (2019)

Endocarditis following ocrelizumab in relapsing-remitting MS
por: Faissner, Simon, et al.
Publicado: (2020)

Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study)
por: Okai, Annette F., et al.
Publicado: (2019)

Gender disparities in health resource utilization in patients with relapsing–remitting multiple sclerosis: a prospective longitudinal real-world study with more than 2000 patients
por: Schriefer, Dirk, et al.
Publicado: (2020)

Autoimmune hemolytic anemia, demyelinating relapse, and AQP1 antibodies after alemtuzumab infusion
por: Tzartos, John S., et al.
Publicado: (2020)

Designing an Electronic Patient Management System for Multiple Sclerosis: Building a Next Generation Multiple Sclerosis Documentation System
por: Kern, Raimar, et al.
Publicado: (2016)

Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies
por: Dayan, Colin M., et al.
Publicado: (2023)

Lymphocyte Counts and Multiple Sclerosis Therapeutics: Between Mechanisms of Action and Treatment-Limiting Side Effects
por: Fischer, Stefanie, et al.
Publicado: (2021)

Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis
por: Proschmann, Undine, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nj6lbkvis3di8l93vs8d2mc4vg